Compulsive behaviors in patients with Parkinson's disease

Neurologist

Volumn 16, Issue 3, 2010, Pages 192-195

  Kenangil, Gülay ^a   Özekmekçi, Sibel ^a   Sohtaoglu, Melis ^a   Erginöz, Ethem ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Compulsive behavior; Dopamine agonist; Impulse control disorder; L DOPA; Parkinson's disease

Indexed keywords

CABERGOLINE; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE;

ADULT; ARTICLE; COMPULSION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; EATING DISORDER; FEMALE; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL;

ADULT; AGED; ANTIPARKINSON AGENTS; BINGE-EATING DISORDER; BRAIN; COMORBIDITY; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAMBLING; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PARKINSON DISEASE; PREVALENCE; RISK FACTORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SUBSTANCE-RELATED DISORDERS;

EID: 77952018642     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31819f952b     Document Type: Article

References (38)

1. Evans AH, Lees AJ. Dopamin dysregulation syndrome in Parkinson's disease. Curr Opin Neurol. 2004; 17: 393-398.
2. Miyasaki JM, Al Hassan K, Lang AE, et al. Punding prevalence in Parkinson's disease. Mov Disord. 2007; 22: 1179-1181.
3. Giovannoni G, O'sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000; 68: 423-428.
4. Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008; 14: 89-99.
5. Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of Hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord. 2005; 20: 77-81.
6. Pontone G, Williams JR, Bassett SS, et al. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006; 67: 1258-1261.
7. Voon V, Hassan K, Zurowski M, et al. Prospective prevalance of pathological gambling and medication association in Parkinson's disease. Neurology. 2006; 66: 1750-1752. (Pubitemid 43964638)
8. Gallagher DA, O'Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord. 2007; 22: 1757-1763.
9. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology. 2003; 61: 422-423.
10. Dodd MI, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005; 62: 1377-1381.
11. Voon V, Hassan K, Zurowski M, et al. Prevalance of repetitive and rewardseeking behaviors in Parkinson's disease. Neurology. 2006; 67: 1254-1257.
12. Weintraub D, Siderowf AD, Potenza MN, et al. Dopamine agonist use is associated with impulse control disorders in Parkinson's disease. Arch Neurol. 2006; 63: 969-973.
13. Klos KJ, Bower JH, Josephs KA, et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson disease and multiple system atrophy. Parkinsonism Relat Disord. 2005; 11: 381-386.
14. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006; 21: 524-529.
15. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's Disease: its relation to the dopamine dysregulation syndrome. Mov Disord. 2004; 19: 397-405.
16. Fernandez HH, Friedman JH. Punding on L-Dopa. Mov Disord. 1999; 14: 836-838.
17. Lawrence AJ, Blackwell AD, Barker RA, et al. Predictors of punding in Parkinson's disease: results from a questionnaire survey. Mov Disord. 2007; 22: 2339-2345.
18. Evans AH, Lawrence AD, Potts J, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson's disease. Neurology. 2005; 65: 1570-1574.
19. Giladi N, Weitzman N, Schreiber S, et al. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol. 2007; 21: 501-506.
20. McKeon A, Josephs KA, Klos KJ, et al. Unusual compulsive behaviors primarily to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord. 2007; 13: 516-519.
21. Grosset KA, Macphee G, Pal G, et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord. 2006; 21: 2206-2208.
22. Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord. 2008; 23: 75-80.
23. Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992; 42: 1142-1146.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
25. Molina JA, Sainz-Artiga MJ, Jimenez-Jimenez FJ, et al. Pathological gambling in Parkinson's disease. Parkinsonism Relat Disord. 1999; 5 (suppl) : 90.
26. Uitti RJ, Tanner CM, Rajput AH, et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989; 12: 375-383.
27. Folstein MF, Folstein SE, McHugh PR. Mini mental state. A practical method for grading the cognitive state of patients for clinician. J Psychiatr Res. 1975; 12: 189-198.
28. Fahn S, Elton RS, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al. eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Publishers; 1987: 53-163.
29. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain. 2000; 123: 733-745.
30. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow? Neurology. 1999; 52: 1227-1229.
31. Grosset K, Needleman F, Macphee G, et al. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord. 2004; 19: 1370-1374.
32. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007; 64: 212-216.
33. Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord. 2008; 14: 28-32.
34. Isaias IU, Siri C, Cilia R, et al. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord. 2008; 23: 411-415.
35. Imamura A, Uitti RJ, Wszolek ZK. Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism Relat Disord. 2006; 12: 506-508.
36. Grosset KA, Grosset DG, Macphee G, et al. Dopamine agonists and pathological gambling. Parkinsonism Relat Disord. 2007; 13: 259.
37. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000; 15: 869-872.
38. Bearn J, Evans A, Kelleher M, et al. Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend. 2004; 76: 305-310.